Using osimertinib to prevent progression of lung cancer nodules after surgery

A Phase II Study of Osimertinib to Suppress the Progression of Remaining Ground-glass Opacity Nodule (GGN) for Actionable EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

This study is testing if the drug osimertinib can help prevent lung cancer nodules from getting worse in patients who have had surgery for their cancer.

Quick facts

• Phase: PHASE2
• Study type: Interventional
• Enrollment: 59 (estimated)
• Ages: 30 Years to 75 Years
• Sex: All
• Sponsor: Samsung Medical Center (other)
• Drugs / interventions: osimertinib, chemotherapy, radiation
• Locations: 1 site (Seoul)
• Trial ID: NCT05528458 on ClinicalTrials.gov

What this trial studies

This open-label, phase II study evaluates the effectiveness of osimertinib, administered at a dose of 80 mg orally once daily, in preventing the progression of remaining ground-glass opacity nodules (GGNs) in patients with EGFR mutation-positive stage IB-IIIA lung adenocarcinoma following surgical resection. The study focuses on patients who have undergone complete surgical removal of their primary lung cancer and have persistent GGNs in other lobes. By analyzing the genetic profiles of these lesions, the study aims to establish a standardized approach for managing this distinct disease entity.

Who should consider this trial

Good fit: Ideal candidates are adults aged 30 to 75 with pathologically confirmed lung adenocarcinoma and persistent GGNs following surgical resection.

Not a fit: Patients with non-EGFR mutation-positive lung adenocarcinoma or those who have not undergone complete surgical resection may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly reduce the risk of cancer progression in patients with remaining GGNs after surgery.

How similar studies have performed: While there have been studies on osimertinib for lung cancer, this specific approach targeting GGNs is relatively novel and has not been extensively tested.

Eligibility criteria

Inclusion Criteria:

1. Provision of informed consent prior to any study specific procedures
2. Adult male or female patients, aged from 30 to 75 years
3. Pathologic proven lung adenocarcinoma with additional persistent GGNs in at least one other lobe: GGN is defined as a ground glass-opacity with well-defined margin, mean density above -500 HU and greater than 7.5 mm in its maximum diameter
4. The resected lung adenocarcinoma should have actionable EGFR mutation, which is limited to L858R or exon 19 deletion.
5. WHO performance status 0-1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks
6. Complete surgical resection of the primary NSCLC is mandatory.
7. Uneventful recovery from curative-intent lung cancer surgery

For assignment in the control arm, subjects should be classified post-operatively as Stage IA on the basis of pathologic criteria (the 8th edition of TNM staging system for lung cancer).

For assignment in the treatment arm, subjects should fulfil the following criteria in addition to the above criteria.

* Patients must be classified post-operatively as Stage IB, II or IIIA on the basis of pathologic cirteria (the 8th edition of TNM staging system for lung cancer)
* Female subjects should be using highly effective contraceptive measures, and must have a negative pregnancy test and not be breast-feeding prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:

  * Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments
  * Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution
  * Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation

Further information in Appendix E (Definition of Women of Childbearing Potential and Acceptable Contraceptive Methods)

\- Male subjects should be willing to use barrier contraception during the study and for 4 months after last dose of osimertinib

Exclusion Criteria:

1. Regression of synchronous GGN after adjuvant chemotherapy prior to osimertinib
2. Past history of postoperative ALI/ARDS or pneumonia during recovery period
3. Currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of CYP3A4 (at least 3 week prior) (Appendix C). All patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer effects on CYP3A4.
4. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.
5. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib.
6. Any of the following cardiac criteria:

   * Mean resting corrected QT interval (QTc) \> 470 msec obtained from 3 electrocardiograms (ECGs), using the screening clinic ECG machine derived QTc value. Whenever QTc, is mentioned in this document, this refers to correction e made by Fridericia formula (QTcF),
   * Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block and second degree heart block.
   * Patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, electrolyte abnormalities (including: Serum/plasma potassium \< lower limit of normal (LLN); Serum/plasma magnesium \< LLN; Serum/plasma calcium \< LLN) , congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes
7. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
8. Inadequate bone marrow reserve or organ function (as demonstrated by any of the following laboratory values:

   * Absolute neutrophil count \<1.5 x 109/L;
   * Platelet count \<100 x 109/L;
   * Haemoglobin \<90 g/L;
   * Alanine aminotransferase \>2.5 times upper limit of normal (ULN) if no demonstrable liver metastases or \>5 times ULN in the presence of liver metastases;
   * Aspartate aminotransferase \>2.5 times ULN if no demonstrable liver metastases or \>5 times ULN in the presence of liver metastases;
   * Total bilirubin \>1.5 times ULN if no liver metastases or \>3 times ULN in the presence of documented Gilbert's Syndrome \[unconjugated hyperbilirubinaemia\] or liver metastases;
   * Serum creatinine \>1.5 times ULN concurrent with creatinine clearance \<50 mL/min \[measured or calculated by Cockcroft and Gault equation\]-confirmation of creatinine clearance is only required when creatinine is \>1.5 times ULN.
9. Women who are breast-feeding
10. Males and females of reproductive potential who are not using and effective method of birth control and females who are pregnant or breastfeeding or have a positive (urine or serum) pregnancy test prior to study entry.
11. Involvement in the planning and conduct of the study (applies to AstraZeneca staff or staff at the study site).
12. History of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib.

Where this trial is running

Seoul

• Sehoon Lee — Seoul, South Korea (RECRUITING)

Study contacts

• Study coordinator: Sehoon Lee, PhD

Conditions: Lung Adenocarcinoma